Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions (ANGEL)

NCT06085833 is registered in ClinicalTrials.gov with ARTIDIS AG as lead sponsor.

NCT NCT06085833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06085833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions (ANGEL)
Lead sponsor
ARTIDIS AG
Phase
Not applicable
Overall status
Recruiting
Start date
November 2, 2023
Completion date
November 30, 2035
Enrollment
2,706 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer